Momenta Phama (MNTA) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Momenta Pharmaceuticals (MNTA) PT Raised to $22 at Stifel
May 8, 2018 1:52 PM EDTStifel raised its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $22.00 (from $21.00) while maintaining a Buy rating.
Analyst Alex Schwartz commented, "Momenta reported 1Q18 earnings that included $4.8 million in revenues, a $47.6 million net loss, and a $346 million cash & equivalents balance. Importantly, Momentas... More
Momenta Pharmaceuticals (MNTA) PT Raised to $23 at Cowen
May 8, 2018 11:59 AM EDTCowen raised its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $23.00 (from $15.00) while maintaining a Market Perform rating following financials and pipeline update.
Analyst Ken Cacciatore commented, "Given the current cash balances combined with what we believe will be an eventual acceleration in 40mg... More
